Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks (approximately 9 ...

Diabetes is a systemic disease, which means it affects many organs, including the heart, blood vessels, nerves, kidneys and ...

Treating people in the early stages of diabetes-related eye disease may help slow the progression of the condition, but a new study also suggests that it can’t help prevent vision loss in the future.

The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 1 and affects nearly 7.7 million people in the U.S. 2 ...

Many people with diabetes have the earliest stage of diabetic retinopathy, called mild nonproliferative diabetic retinopathy (NPDR), without even knowing it, according to the American Academy of ...

New study from University of California, Irvine and University of California, Santa Barbara researchers demonstrates improved retinal function and vascular integrity, supporting further investigation ...

Patients with type 2 diabetes who received intravitreal anti-vascular endothelial growth factor (VEGF) injections for diabetic retinopathy were more likely to develop systemic adverse events (AEs) ...

A report in the December issue of the Archives of Ophthalmology shows that injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of ...

February 7, 2012 — The Diabetic Retinopathy Clinical Research (DRCR) Network is a network of community- and academic-based ophthalmologists that has been conducting clinical research related to ...

A key protein, LRG1, was identified as the early cause of diabetic eye damage, and blocking it may stop the disease before ...

Housing instability, food insecurity and other factors related to social deprivation come with significantly greater risks ...